Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

August 31, 2013

Conditions
Amyotrophic Lateral SclerosisALS
Interventions
BIOLOGICAL

HYNR-CS inj

Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.

OTHER

Control group

No treatment of HYNR-CS inj

Trial Locations (1)

133-792

Hanyang University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Corestemchemon, Inc.

INDUSTRY

NCT01363401 - Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter